Haemonetics reports Q1 FY27 results and raises full-year guidance
Haemonetics increased Q1 FY27 revenue 5.6% and adjusted earnings per share to $1.14; the company raised total company fiscal 2027 guidance driven by strong business momentum.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day